Urological Tumours

Expert assessment and treatment of genitourinary tumours

The Urological Tumours Unit at the Publio Cordón Memorial Hospital specialises in the assessment and medical treatment of cancers affecting the urinary tract — in both men and women — and the male reproductive system, particularly in cases where it is necessary to precisely determine the most appropriate treatment option at each stage of the disease.

This group includes tumours of the prostate, bladder, kidney, testicles and other related structures. These are conditions that require expert assessment and a coordinated approach, capable of integrating different treatment options within an individualised clinical pathway.

The unit’s aim is not merely to prescribe a specific treatment, but to establish a comprehensive treatment plan that takes into account the progression of the disease, its biological characteristics and the clinical situation of each patient.

When is an assessment indicated?

Care in this unit is indicated for people with a confirmed diagnosis of genitourinary cancer, as well as in cases where it is necessary to determine the treatment following the initial assessment or to reconsider the strategy in light of changes in the course of the disease.

For many patients, decision-making is not simply a matter of choosing a therapy, but of determining the most appropriate sequence from among the various available options, including systemic treatment, surgery and, in certain cases, radiotherapy. This planning requires a specialist assessment capable of organising decisions judiciously and at the appropriate time.

The diversity of these tumours, as well as the differences in their clinical and biological behaviour, make an expert assessment particularly important in order to guide treatment with precision.

Main tumours assessed by the unit

The approach is tailored to the type of tumour, its location, extent, biological characteristics and the overall clinical context of each patient. The unit specialises in the assessment of:

• Prostate cancer

• Bladder cancer

• Kidney tumours

• Testicular tumours

• Penile tumours

• Metastatic disease of genitourinary origin

Each case is assessed individually, taking into account not only disease control but also the possibility of adapting treatment over time in line with clinical progress.

Clinical assessment and treatment planning

The process begins with a detailed clinical assessment that incorporates histological diagnosis, imaging tests and, where indicated, biomarker analysis. This information enables a better understanding of the tumour’s behaviour and allows for more precise guidance in treatment decisions.

Based on this analysis, each case is reviewed within a multidisciplinary committee comprising specialists in Medical Oncology, Urology, Radiology, Radiation Oncology and Pathology. This collaborative approach provides a more comprehensive view of the disease and enables the various stages of treatment to be rigorously coordinated.

The approach is conceived as a dynamic process, in which the sequence of interventions can be reviewed and adjusted according to the progression of the disease and the response achieved.

Personalised cancer treatment

Medical treatment is tailored to the individual, taking into account the type of tumour, its biological profile, the extent of the disease and the patient’s clinical condition. In many genitourinary tumours, this assessment is crucial for selecting the most appropriate treatment option at any given time.

Systemic treatment is an essential component of the approach and includes various therapeutic strategies tailored to each clinical context. In prostate cancer, hormonal therapies, new targeted agents and, in advanced stages, chemotherapy may be used. In bladder and kidney tumours, immunotherapy and certain targeted therapies have come to play a significant role in specific situations.

The indication for each treatment is based on current scientific evidence and an individual assessment of each patient, and is adjusted over time according to the progression of the disease, clinical response and tolerability.

Follow-up and monitoring of disease progression

Clinical follow-up enables us to assess the response to treatment, detect changes in the course of the disease and adjust the treatment strategy where necessary. This ongoing monitoring is an essential part of the management of genitourinary tumours, as many decisions need to be reviewed at different stages of the process.

Follow-up appointments are organised on an individual basis and enable not only the treatment to be adapted, but also side effects to be monitored and close coordination to be maintained with the other specialities involved in the patient’s care.

Support and guidance throughout the process

A diagnosis of a genitourinary tumour often involves decisions that unfold over time and require a clear understanding of the various treatment options.

From the very first consultation, we take the time needed to explain the clinical situation, the significance of the tests, the treatment options and the expected course of the condition in each individual case. The information is tailored to each patient’s needs, with the aim of facilitating a genuine understanding of the process and helping them make decisions with greater confidence.

Support is provided throughout the entire care journey, with close and ongoing communication that enables patients to resolve any doubts, anticipate decisions and approach treatment with greater confidence.